After decades with no targeted treatments, patients with systemic mastocytosis finally have real pharmaceutical options — and the pipeline is still growing. The FDA approved midostaurin in 2017 as the first targeted therapy for advanced forms of the disease, followed by avapritinib in 2021 and 2023 for both advanced and indolent subtypes. Now, bezuclastinib, a next-generation drug developed by Cogent Biosciences, had its New Drug Application accepted by the FDA on March 16, 2026, with a target action date of December 30, 2026. If approved, it would become the third targeted therapy for systemic mastocytosis in under a decade — a remarkable turnaround for a disease that was essentially untreatable with precision medicine before 2017.
Systemic mastocytosis is a rare condition affecting roughly 32,000 people in the United States, caused by the abnormal accumulation of mast cells in organs throughout the body. The average age at diagnosis is 60, which places this squarely within the demographic most relevant to readers concerned about aging, chronic disease management, and long-term brain health. Mast cell disorders can produce a bewildering range of symptoms — from skin flushing and gastrointestinal distress to bone pain and cognitive fog — and the overlap with other conditions common in older adults has contributed to significant underdiagnosis. This article walks through the full treatment timeline, from the years of having nothing targeted to offer patients, through each approval milestone, and into the clinical trial data behind bezuclastinib. We will also address the practical realities of cost, access, side effects, and what these developments might mean for patients and caregivers navigating complex chronic illness.
Table of Contents
- What New Drugs Have Been Approved for Systemic Mastocytosis After Years of No Options?
- How Avapritinib Changed the Landscape for the Most Common Form of Systemic Mastocytosis
- Bezuclastinib’s Clinical Trial Results and Why They Matter
- Comparing the Three Targeted Therapies for Systemic Mastocytosis
- Why Systemic Mastocytosis Is Frequently Misdiagnosed in Older Adults
- The Role of Caregivers in Managing a Rare Disease Diagnosis
- What the Next Few Years Could Bring for Systemic Mastocytosis Treatment
- Conclusion
- Frequently Asked Questions
What New Drugs Have Been Approved for Systemic Mastocytosis After Years of No Options?
Before 2017, physicians treating systemic mastocytosis were limited to symptomatic management — antihistamines, corticosteroids, and other broad-spectrum approaches that did nothing to address the underlying biology of the disease. The breakthrough came when researchers identified that the KIT D816V mutation drives approximately 95 percent of systemic mastocytosis cases. That single molecular target opened the door to precision medicine. Midostaurin, marketed as Rydapt, became the first FDA-approved targeted therapy on April 28, 2017. Developed by Novartis, it was approved for advanced subtypes including aggressive systemic mastocytosis, SM with an associated hematological neoplasm, and mast cell leukemia. In clinical trials, it produced complete or incomplete remission in 38 percent of patients with aggressive SM and 16 percent of those with SM-AHN.
Those numbers were modest, but for a patient population that previously had no targeted options at all, they represented a genuine shift. The drug is taken orally at 100 mg twice daily, though gastrointestinal side effects — nausea, vomiting, diarrhea — remain a common complaint and can limit tolerability. Avapritinib, sold as Ayvakit, raised the bar considerably. Blueprint Medicines secured FDA approval in June 2021 for advanced SM, and then again on May 22, 2023, for indolent systemic mastocytosis — making it the first and only approved therapy for ISM, which is by far the most common subtype. Where midostaurin cast a wider net across kinase targets, avapritinib was designed with high selectivity for the KIT D816V mutation. That precision translated into stronger clinical outcomes and a more manageable side effect profile for many patients.
How Avapritinib Changed the Landscape for the Most Common Form of Systemic Mastocytosis
The approval of avapritinib for indolent SM in may 2023 was arguably the most consequential regulatory decision in this disease space. Indolent SM accounts for the majority of systemic mastocytosis cases, and patients with this subtype often endure years of debilitating symptoms — unpredictable flushing, abdominal cramping, bone pain, fatigue, and cognitive difficulties sometimes described as “brain fog” — without organ damage severe enough to qualify them for treatments approved only for advanced disease. For years, these patients fell into a therapeutic gap: sick enough to suffer, not sick enough for the drugs that existed. The PIONEER trial, which enrolled 212 patients across 49 sites in 13 countries, provided the evidence base for the ISM approval. At 24 weeks, patients receiving avapritinib at 25 mg once daily showed a mean total symptom score improvement of negative 15.6 points compared to negative 9.2 for placebo, a statistically significant difference. By 48 weeks in the open-label extension, that improvement deepened to negative 20.2 points.
Perhaps more striking was the biomarker response: 53.9 percent of patients on avapritinib achieved at least a 50 percent reduction in serum tryptase levels, compared to zero percent in the placebo group. Ninety-six percent of patients completed treatment, suggesting the drug was well tolerated overall. However, avapritinib’s price presents a serious barrier. At approximately $38,929 per month — roughly $490,000 per year — it is among the more expensive specialty medications on the market. Blueprint Medicines reports that 98 percent of commercial insurance plans and 99 percent of Medicare plans cover the drug, but coverage does not eliminate the problem of copays, prior authorizations, and step therapy requirements that can delay access. For older adults on fixed incomes, even a modest copay percentage of a half-million-dollar annual drug cost can be prohibitive without manufacturer assistance programs.
Bezuclastinib’s Clinical Trial Results and Why They Matter
Bezuclastinib, developed by Cogent Biosciences, has generated considerable attention because its clinical trial data appears to surpass what avapritinib achieved. The SUMMIT Phase 2 trial reported a mean total symptom score improvement of negative 24.3 points versus negative 15.4 for placebo at 24 weeks — a larger absolute difference than seen in the PIONEER trial. The biomarker responses were even more dramatic: 87.4 percent of patients achieved at least a 50 percent reduction in serum tryptase, compared to zero percent for placebo. At 48 weeks, that figure rose to 98.9 percent. The drug also showed impressive effects on disease burden at a cellular level. Among patients in the SUMMIT trial, 75.6 percent achieved at least a 50 percent reduction in bone marrow mast cells, and 85.7 percent achieved at least a 50 percent reduction in KIT D816V variant allele frequency.
Eighty-three percent of patients had tryptase levels normalized below 20 ng/mL. By 48 weeks, 86 percent of patients achieved at least a 30 percent reduction in total symptom scores. These are the kind of response rates that, if they hold up in the confirmatory data submitted to the FDA, could position bezuclastinib as the preferred first-line therapy. The side effect profile also appears manageable, though not without quirks. The most commonly reported adverse events were hair color changes, nausea, and diarrhea — all described as low-grade and reversible. Hair color changes are an unusual side effect that reflects the drug’s mechanism of action on KIT signaling, which plays a role in melanocyte function. It is worth noting that cross-trial comparisons between bezuclastinib and avapritinib should be interpreted cautiously, as the patient populations, trial designs, and endpoints were not identical.
Comparing the Three Targeted Therapies for Systemic Mastocytosis
For patients and their physicians, the practical question is which therapy fits a given clinical situation. Midostaurin remains the only option with long-term follow-up data for advanced subtypes, but its response rates are the lowest of the three drugs — 38 percent complete or incomplete remission in aggressive SM — and its twice-daily dosing with frequent gastrointestinal side effects makes it less appealing for long-term use. It was a necessary first step, not the destination. Avapritinib currently holds the strongest position: it is the only drug approved for both advanced and indolent SM, it has a once-daily 25 mg dosing schedule for ISM, and its selectivity for KIT D816V gives it a cleaner mechanism. The PIONEER trial’s 96 percent treatment completion rate speaks to its tolerability. But the annual cost approaching half a million dollars is a real constraint, and not every patient responds to the same degree.
Some patients may not tolerate it due to cognitive effects that have been reported at higher doses used in advanced disease, though the 25 mg ISM dose appears to carry a lower risk. Bezuclastinib, if approved, could offer the strongest symptom and biomarker improvements based on available data. The FDA granted it Breakthrough Therapy Designation for non-advanced SM, which typically signals that regulators view the drug as a substantial improvement over existing options. Cogent Biosciences is also pursuing an NDA for advanced SM in the first half of 2026. The key unknown is pricing — if bezuclastinib enters the market at a similar price point to avapritinib, competition alone may not be enough to improve affordability. If it comes in lower, it could meaningfully expand access.
Why Systemic Mastocytosis Is Frequently Misdiagnosed in Older Adults
One of the most persistent problems in systemic mastocytosis care is not the lack of drugs — it is the failure to diagnose the disease in the first place. Global prevalence is estimated at roughly 1 in 10,000 people, but experts believe the true number is higher because many cases are never identified. The symptoms of SM — flushing, gastrointestinal problems, fatigue, bone pain, cognitive difficulties — overlap substantially with conditions that are common in older adults, including irritable bowel syndrome, osteoporosis, menopause, anxiety disorders, and age-related cognitive decline. For readers of a brain health and dementia care site, the cognitive dimension deserves particular attention.
Mast cell activation can release histamine and other inflammatory mediators that cross the blood-brain barrier, contributing to what patients often describe as brain fog — difficulty concentrating, word-finding problems, and short-term memory lapses. In an older adult already being monitored for cognitive changes, these symptoms might be attributed to early dementia or normal aging rather than an underlying mast cell disorder. A serum tryptase level, which is a straightforward blood test, can provide an important clue, though it is not always included in standard workups. The practical warning here is that a diagnosis of systemic mastocytosis requires a high index of suspicion. If an older adult presents with the combination of unexplained flushing, gastrointestinal distress, osteoporosis that seems disproportionate to their risk factors, and cognitive symptoms, it is worth asking whether a mast cell disorder could be contributing — particularly now that effective treatments exist.
The Role of Caregivers in Managing a Rare Disease Diagnosis
For families already navigating dementia care or other complex conditions in an aging loved one, a systemic mastocytosis diagnosis can feel overwhelming. Rare diseases come with their own learning curve: finding a specialist, understanding insurance coverage for expensive medications, coordinating between hematologists and other providers, and managing a treatment regimen that may require regular blood work and monitoring. Caregiver involvement can be especially important for older patients with SM who also have cognitive impairment.
Keeping track of medication schedules — particularly for a drug like midostaurin that requires twice-daily dosing with food — falls to the caregiver when the patient cannot manage it independently. Patient assistance programs offered by manufacturers like Blueprint Medicines and potentially Cogent Biosciences can help defray costs, but someone has to navigate the application process. The Mastocytosis Society and other patient advocacy organizations maintain resources that can help families find experienced physicians and connect with others managing the same diagnosis.
What the Next Few Years Could Bring for Systemic Mastocytosis Treatment
The trajectory of drug development for systemic mastocytosis has been steep. From zero targeted therapies before 2017 to potentially three approved agents by the end of 2026, the field has moved faster than many rare disease advocates dared to hope. The FDA’s acceptance of the bezuclastinib NDA and the December 30, 2026 PDUFA date suggest that regulators are treating this application with standard priority, which is a positive signal after the Breakthrough Therapy Designation.
Beyond bezuclastinib, the deeper shift is in how the disease is understood. As more effective treatments become available, the incentive to diagnose SM earlier increases — which could benefit the estimated population of undiagnosed patients who are currently managing their symptoms without knowing the cause. For older adults and their families, this means that persistent, unexplained multi-system symptoms deserve a closer look, especially when a simple blood test could point toward a treatable condition. The era of having nothing to offer patients with systemic mastocytosis is over, and the next chapter looks to be one of refinement rather than desperation.
Conclusion
Systemic mastocytosis has gone from a disease with no precision therapies to one with a growing arsenal of targeted drugs in less than a decade. Midostaurin opened the door in 2017, avapritinib expanded access to the most common form of the disease in 2023, and bezuclastinib may soon offer even stronger clinical responses if approved by its December 2026 target date. For the estimated 32,000 people in the United States living with SM — many of them older adults whose symptoms may overlap with other age-related conditions — these developments represent a meaningful change in what is possible.
The most important takeaway for patients, caregivers, and anyone involved in the care of aging adults is that unexplained symptoms deserving of investigation should not be written off as inevitable consequences of getting older. Systemic mastocytosis is rare, but it is also underdiagnosed and now treatable. Asking the right questions and pursuing the right tests can connect patients with therapies that were simply unavailable a few years ago.
Frequently Asked Questions
What is systemic mastocytosis and how common is it?
Systemic mastocytosis is a rare disease caused by the abnormal accumulation of mast cells in organs such as the bone marrow, liver, spleen, and gastrointestinal tract. It affects approximately 32,000 people in the United States, with a global prevalence estimated at roughly 1 in 10,000. The KIT D816V mutation drives approximately 95 percent of cases.
What drugs are currently approved for systemic mastocytosis?
Two targeted therapies are currently FDA-approved: midostaurin (Rydapt), approved in April 2017 for advanced subtypes, and avapritinib (Ayvakit), approved in June 2021 for advanced SM and in May 2023 for indolent SM. A third drug, bezuclastinib, has an NDA under FDA review with a target decision date of December 30, 2026.
How much does avapritinib cost and is it covered by insurance?
Avapritinib costs approximately $38,929 per month, or roughly $490,000 per year. According to the manufacturer, it is covered by 98 percent of commercial insurance plans and 99 percent of Medicare plans. Manufacturer assistance programs may help with out-of-pocket costs.
Can systemic mastocytosis cause cognitive symptoms like brain fog?
Yes. Mast cell activation releases histamine and other inflammatory mediators that can affect brain function, leading to difficulty concentrating, word-finding problems, and short-term memory issues. In older adults, these symptoms can be mistaken for early dementia or normal age-related cognitive decline.
How strong are the clinical trial results for bezuclastinib?
In the SUMMIT Phase 2 trial, bezuclastinib showed a mean total symptom score improvement of negative 24.3 points versus negative 15.4 for placebo at 24 weeks. At 48 weeks, 98.9 percent of patients achieved at least a 50 percent reduction in serum tryptase levels, and 86 percent achieved at least a 30 percent reduction in total symptom scores.
What are the side effects of the newer systemic mastocytosis drugs?
Avapritinib at the 25 mg dose for indolent SM is generally well tolerated, with 96 percent of PIONEER trial patients completing treatment. Bezuclastinib’s most common side effects in trials were hair color changes, nausea, and diarrhea, described as low-grade and reversible. Midostaurin is associated with more frequent gastrointestinal side effects including nausea and vomiting.
